Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

Integrating genomic prognostic and hallmark signatures from Decipher GRID to predict adverse outcomes in men on active surveillance for prostate cancer.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

Add Yahoo as a preferred source to see more of our stories on Google. Researchers say they've developed a urine test that could answer whether prostate cancer is ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

In a recent study published in the journal Nutrients, researchers investigated the associations between urinary bisphenol A (BPA) concentrations (exposure) and the prostate-specific antigen (PSA; ...